---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-12T14:15:56.435557'
end_time: '2026-02-12T14:20:20.401927'
duration_seconds: 263.97
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dientamoebiasis
  mondo_id: ''
  category: Infectious Disease
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 5
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Dientamoebiasis
- **MONDO ID:**  (if available)
- **Category:** Infectious Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Dientamoebiasis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Dientamoebiasis
- **MONDO ID:**  (if available)
- **Category:** Infectious Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Dientamoebiasis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Disease Pathophysiology Research Report

Target Disease
- Disease Name: Dientamoebiasis (infection with Dientamoeba fragilis)
- MONDO ID: Not confirmed in the present evidence scan
- Category: Infectious Disease

Executive Summary
- Current understanding of the pathophysiology of Dientamoeba fragilis remains limited and controversial. Evidence in recent literature highlights that clinical outcomes range from asymptomatic carriage to symptomatic gastrointestinal disease, and some authors argue D. fragilis may behave as a commensal in many hosts. This uncertainty directly affects mechanistic inferences, disease staging, and clinical decision-making (ganci2023theeffectof pages 13-13).

1. Core Pathophysiology
- Primary mechanisms: The mechanistic basis by which Dientamoeba fragilis would cause host tissue injury or inflammation has not been clearly established in the recent literature sampled here. Contemporary sources emphasize heterogeneity in host outcomes, from potential health benefits/benign carriage to severe illness, implying that if pathogenic mechanisms exist, they may be context dependent (e.g., host factors, co-infections, microbiome state) (ganci2023theeffectof pages 13-13). Direct quote: “Health outcomes associated with … Dientamoeba fragilis are disparate and controversial, ranging from health benefits, to years of asymptomatic carriage, through to severe illness.” URL: https://doi.org/10.1007/s12144-021-01700-z; Publication date: April 2023 (ganci2023theeffectof pages 13-13).
- Molecular pathways: No consistent host signaling or parasite virulence pathways (e.g., cytokine profiles, barrier dysfunction, specific proteases/adhesins) are supported by the evidence retrieved here. The same 2023 source underscores ongoing debate over pathogenicity rather than delineating defined molecular injury cascades (ganci2023theeffectof pages 13-13).
- Cellular processes: Specific epithelial injury, mucus barrier disruption, or immune-cell activation pathways attributable to D. fragilis remain insufficiently defined in the evidence retrieved; the dominant theme is uncertainty over pathogenicity and effect size in humans (ganci2023theeffectof pages 13-13).

2. Key Molecular Players
- Genes/Proteins: No parasite genes or host molecular mediators can be conclusively identified from the present evidence as causal in disease expression for dientamoebiasis (ganci2023theeffectof pages 13-13).
- Chemical Entities (metabolites/drugs): Not supported by the present evidence scan (ganci2023theeffectof pages 13-13).
- Cell Types: No specific cell-type targeting (e.g., colonocytes, goblet cells, macrophages, dendritic cells) can be confirmed from the present evidence (ganci2023theeffectof pages 13-13).
- Anatomical Locations: D. fragilis colonizes the large intestine; however, detailed site-specific pathology cannot be substantiated from the retrieved source (ganci2023theeffectof pages 13-13).

3. Biological Processes (GO annotation candidates)
- Due to the paucity of mechanistic data in the retrieved evidence, no specific GO processes (e.g., epithelial tight junction modulation, cytokine-mediated signaling, innate immune activation) can be confidently annotated for D. fragilis pathophysiology at this time (ganci2023theeffectof pages 13-13).

4. Cellular Components
- No confident assignments (e.g., apical tight junctions, mucus layer, lamina propria immune niches) are possible from the present evidence (ganci2023theeffectof pages 13-13).

5. Disease Progression
- Sequence of events: A reproducible sequence from colonization to symptoms is not delineated in the retrieved evidence. The 2023 source stresses the spectrum from asymptomatic carriage to possible disease, highlighting the need for additional, mechanistic human and experimental studies (ganci2023theeffectof pages 13-13).
- Stages/Phases: Not defined in the present evidence (ganci2023theeffectof pages 13-13).

6. Phenotypic Manifestations
- Clinical phenotypes: Reports in the literature span asymptomatic carriage to gastrointestinal complaints; however, the retrieved 2023 evidence emphasizes that “evidence that … D. fragilis are not necessarily pathogenic and are likely to be part of a diverse gut [microbiota]” is increasing (directly quoted). URL: https://doi.org/10.1007/s12144-021-01700-z; Publication date: April 2023 (ganci2023theeffectof pages 13-13).
- Interpretation: Given the uncertainty, phenotype-pathophysiology links (e.g., diarrhea due to epithelial inflammation) cannot be asserted with confidence from the evidence at hand (ganci2023theeffectof pages 13-13).

Expert Opinions and Analysis
- A recent (2023) peer-reviewed article explicitly frames D. fragilis pathogenicity as “disparate and controversial,” and notes growing evidence for commensal status in many individuals, tempering assumptions about inherent pathogenicity and urging careful interpretation of positive tests in clinical practice (URL: https://doi.org/10.1007/s12144-021-01700-z; Apr 2023) (ganci2023theeffectof pages 13-13).

Current Applications and Real-World Implementations
- Diagnostics and management: The retrieved 2023 article chiefly contextualizes D. fragilis within broader debates of commensalism versus pathogenicity and does not provide definitive, mechanism-based diagnostic biomarkers or targeted therapies. Clinical decisions may require integration of symptom profiles, exclusion of alternative causes, and cautious interpretation of detection results in light of uncertain pathogenicity (ganci2023theeffectof pages 13-13).

Relevant Statistics and Data from Recent Studies
- The 2023 article is a cross-sectional retrospective study focusing on psychological symptom domains; it does not provide mechanistic pathophysiology statistics. Its key contribution is evidentiary framing: absence of a clear association between protozoan carriage and psychological symptom severity and the broader statement about contested pathogenicity (URL: https://doi.org/10.1007/s12144-021-01700-z; Apr 2023) (ganci2023theeffectof pages 13-13).

Structured Annotations (provisional; constrained by available evidence)
- Gene/Protein (HGNC): None supported (ganci2023theeffectof pages 13-13)
- Biological Process (GO): None supported (ganci2023theeffectof pages 13-13)
- Cellular Component (GO): None supported (ganci2023theeffectof pages 13-13)
- Cell Type (CL): None supported (ganci2023theeffectof pages 13-13)
- Anatomical Location (UBERON): Large intestine (colon) – not explicitly documented in the retrieved excerpt; mechanistic localization cannot be substantiated here (ganci2023theeffectof pages 13-13)
- Phenotype (HPO): Asymptomatic carriage vs. gastrointestinal symptoms are debated; no definitive HPO mapping from the retrieved excerpt (ganci2023theeffectof pages 13-13)
- Chemical Entity (CHEBI): None supported (ganci2023theeffectof pages 13-13)

Evidence Items
- Ganci M, Butt H, Tyrrell J, Suleyman E, Ball M. The effect of Blastocystis sp. and Dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females. Current Psychology. 2023 Apr;42:4017–4030. DOI: 10.1007/s12144-021-01700-z. URL: https://doi.org/10.1007/s12144-021-01700-z. Key quotes: “Health outcomes associated with Blastocystis sp. and Dientamoeba fragilis are disparate and controversial, ranging from health benefits, to years of asymptomatic carriage, through to severe illness.” “These findings add weight to the argument that Blastocystis sp. and D. fragilis are not necessarily pathogenic and are likely to be part of a diverse gut [microbiota].” (ganci2023theeffectof pages 13-13)

Limitations and Gaps
- The present evidence scan captured one 2023 peer-reviewed article that frames the overarching controversy but does not provide molecular/cellular mechanisms for D. fragilis pathophysiology. Many key mechanistic topics—host immune signaling, barrier disruption, parasite virulence factors, and disease staging—remain unaddressed here due to lack of accessible full texts within this search session. Accordingly, this report is partial and emphasizes the current uncertainty documented in the 2023 source (ganci2023theeffectof pages 13-13).

Recommendations for Further Evidence Acquisition
- Targeted retrieval of recent (2023–2024) mechanistic studies and reviews on: D. fragilis–epithelium interactions, cytokine/chemokine responses, barrier integrity assays, protease/adhesin characterization, transcriptomics/genomics of D. fragilis, and controlled clinical studies correlating organism burden with mucosal inflammation and symptoms. Priority should be given to primary literature with PMIDs and authoritative reviews summarizing mechanistic data.


References

1. (ganci2023theeffectof pages 13-13): Michael Ganci, Henry Butt, Jean Tyrrell, Emra Suleyman, and Michelle Ball. The effect of blastocystis sp. and dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females. Current Psychology, 42:4017-4030, Apr 2023. URL: https://doi.org/10.1007/s12144-021-01700-z, doi:10.1007/s12144-021-01700-z. This article has 5 citations and is from a peer-reviewed journal.